{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T02:06:09Z","timestamp":1768961169368,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA142081"],"award-info":[{"award-number":["R01CA142081"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA237318"],"award-info":[{"award-number":["R01CA237318"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,1,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic inflammation and inflammatory-related exposures have been implicated in epithelial ovarian cancer (EOC) prognosis. However, no studies have evaluated whether analgesic medication use impacts survival in Black women with EOC, an understudied population with poor survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Leveraging data from the African American Cancer Epidemiology Study, we examined the association of pre-diagnostic analgesic medication use (aspirin, non-aspirin non-steroidal anti-inflammatory drugs [naNSAIDs], and acetaminophen) with survival among self-identified Black women diagnosed with EOC (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009541) using multivariable Cox proportional hazards regression. Stratified analyses were conducted by comorbidities and histotype.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Acetaminophen use was associated with a higher risk of mortality overall (HR\u2009=\u20091.40; 95% CI\u2009=\u20091.00\u20131.97) and for frequent and chronic use (\u226530 days per month: HR\u2009=\u20091.62; 95% CI\u2009=\u20091.12\u20132.34; &gt;5 years: HR\u2009=\u20091.57; 95% CI\u2009=\u20091.03\u20132.39). These associations were more pronounced among women with high-grade serous carcinoma (HGSC)\/carcinosarcoma and those with comorbidities. Among women with comorbidities, naNSAID use was associated with a decreased risk of mortality (HR\u2009=\u20090.71; 95% CI\u2009=\u20090.51\u20130.99), but no association was observed among women without comorbidities (HR\u2009=\u20090.99; 95% CI\u2009=\u20090.56\u20131.75). No associations with survival were observed for aspirin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Chronic use of acetaminophen negatively impacted survival among Black women with EOC, while naNSAID use conferred a survival advantage only among women with comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-025-03254-4","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T09:58:03Z","timestamp":1762336683000},"page":"237-244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of non-prescription analgesic medications and survival among Black women with ovarian cancer"],"prefix":"10.1038","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8118-9591","authenticated-orcid":false,"given":"Christelle","family":"Colin-Leitzinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Aranzabal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Alberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa V.","family":"Bandera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Bondy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele L.","family":"Cote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa A.","family":"Hastert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Haller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward S.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D.","family":"Terry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0990-9339","authenticated-orcid":false,"given":"Joellen M.","family":"Schildkraut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-8600","authenticated-orcid":false,"given":"Lauren C.","family":"Peres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"3254_CR1","doi-asserted-by":"publisher","first-page":"580289","DOI":"10.3389\/fphar.2020.580289","volume":"11","author":"N Ohashi","year":"2020","unstructured":"Ohashi N, Kohno T. Analgesic effect of acetaminophen: a review of known and novel mechanisms of action. Front Pharmacol. 2020;11:580289.","journal-title":"Front Pharmacol"},{"key":"3254_CR2","first-page":"11","volume":"71","author":"M J\u00f3\u017awiak-Bebenista","year":"2014","unstructured":"J\u00f3\u017awiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm. 2014;71:11\u201323.","journal-title":"Acta Pol Pharm"},{"key":"3254_CR3","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1007\/s000110050284","volume":"47","author":"JR Vane","year":"1998","unstructured":"Vane JR, Botting RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res. 1998;47:S78\u201387.","journal-title":"Inflamm Res"},{"key":"3254_CR4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1001\/jama.2022.4983","volume":"327","author":"US Preventive Services Task Force","year":"2022","unstructured":"US Preventive Services Task Force. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327:1577\u201384.","journal-title":"JAMA"},{"key":"3254_CR5","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1111\/bcp.13656","volume":"84","author":"JC McCrae","year":"2018","unstructured":"McCrae JC, Morrison EE, MacIntyre IM, Dear JW, Webb DJ. Long-term adverse effects of paracetamol\u2014a review. Br J Clin Pharmacol. 2018;84:2218\u201330.","journal-title":"Br J Clin Pharmacol"},{"key":"3254_CR6","doi-asserted-by":"crossref","unstructured":"McEvoy L, Carr DF, Pirmohamed M. Pharmacogenomics of NSAID-induced upper gastrointestinal toxicity. Front Pharmacol. 2021;12:684162.","DOI":"10.3389\/fphar.2021.684162"},{"key":"3254_CR7","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer Statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"3254_CR8","doi-asserted-by":"crossref","unstructured":"Savant SS, Sriramkumar S, O\u2019Hagan HM. The role of inflammation and inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian cancer. Cancers. 2018;10:251.","DOI":"10.3390\/cancers10080251"},{"key":"3254_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1158\/1055-9965.EPI-21-0977","volume":"31","author":"KK Brieger","year":"2022","unstructured":"Brieger KK, Phung MT, Mukherjee B, Bakulski KM, Anton-Culver H, Bandera EV, et al. High prediagnosis inflammation-related risk score associated with decreased ovarian cancer survival. Cancer Epidemiol Biomark Prev. 2022;31:443\u201352.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"3254_CR10","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/s41416-023-02385-w","volume":"129","author":"CE Johnson","year":"2023","unstructured":"Johnson CE, Alberg AJ, Bandera EV, Peres LC, Akonde M, Collin LJ, et al. Association of inflammation-related exposures and ovarian cancer survival in a multi-site cohort study of Black women. Br J Cancer. 2023;129:1119\u201325.","journal-title":"Br J Cancer"},{"key":"3254_CR11","first-page":"537","volume":"30","author":"AN Minlikeeva","year":"2019","unstructured":"Minlikeeva AN, Cannioto R, Jensen A, Kjaer SK, Jordan SJ, Diergaarde B, et al. Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Cancer Causes Control. 2019;30:537\u201347.","journal-title":"Cancer Causes Control"},{"key":"3254_CR12","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1093\/jn\/nxz098","volume":"149","author":"LC Peres","year":"2019","unstructured":"Peres LC, Hebert JR, Qin B, Guertin KA, Bandera EV, Shivappa N, et al. Prediagnostic proinflammatory dietary potential is associated with all-cause mortality among African-American women with high-grade serous ovarian carcinoma. J Nutr. 2019;149:1606\u201316.","journal-title":"J Nutr"},{"key":"3254_CR13","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1158\/1055-9965.EPI-15-0508","volume":"24","author":"AN Minlikeeva","year":"2015","unstructured":"Minlikeeva AN, Freudenheim JL, Lo-Ciganic W-H, Eng KH, Friel G, Diergaarde B, et al. Use of common analgesics is not associated with ovarian cancer survival. Cancer Epidemiol Biomark Prev. 2015;24:1291\u20134.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"3254_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.canep.2014.12.010","volume":"39","author":"CM Nagle","year":"2015","unstructured":"Nagle CM, Ibiebele TI, DeFazio A, Protani MM, Webb PM. Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, acetaminophen and ovarian cancer survival. Cancer Epidemiol. 2015;39:196\u20139.","journal-title":"Cancer Epidemiol"},{"key":"3254_CR15","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/bjc.2017.68","volume":"116","author":"SC Dixon","year":"2017","unstructured":"Dixon SC, Nagle CM, Wentzensen N, Trabert B, Beeghly-Fadiel A, Schildkraut JM, et al. Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. Br J Cancer. 2017;116:1223\u20138.","journal-title":"Br J Cancer"},{"key":"3254_CR16","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/bjc.2017.449","volume":"118","author":"F Verdoodt","year":"2018","unstructured":"Verdoodt F, Kjaer SK, Dehlendorff C, Friis S. Aspirin use and ovarian cancer mortality in a Danish nationwide cohort study. Br J Cancer. 2018;118:611\u20135.","journal-title":"Br J Cancer"},{"key":"3254_CR17","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ygyno.2020.03.028","volume":"157","author":"A Majidi","year":"2020","unstructured":"Majidi A, Na R, Dixon-Suen S, Jordan SJ, Webb PM. Common medications and survival in women with ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol. 2020;157:678\u201385.","journal-title":"Gynecol Oncol"},{"key":"3254_CR18","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S1470-2045(18)30373-5","volume":"19","author":"MA Merritt","year":"2018","unstructured":"Merritt MA, Rice MS, Barnard ME, Hankinson SE, Matulonis UA, Poole EM, et al. Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS\/NHSII): a cohort study. Lancet Oncol. 2018;19:1107\u201316.","journal-title":"Lancet Oncol"},{"key":"3254_CR19","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/bjc.2016.39","volume":"114","author":"LC Peres","year":"2016","unstructured":"Peres LC, Camacho F, Abbott SE, Alberg AJ, Bandera EV, Barnholtz-Sloan J, et al. Analgesic medication use and risk of epithelial ovarian cancer in African American women. Br J Cancer. 2016;114:819\u201325.","journal-title":"Br J Cancer"},{"key":"3254_CR20","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/jnci\/djac239","volume":"115","author":"A Majidi","year":"2023","unstructured":"Majidi A, Na R, Jordan SJ, DeFazio A, Obermair A, Friedlander M, et al. Common analgesics and ovarian cancer survival: the Ovarian Cancer Prognosis and Lifestyle (OPAL) Study. J Natl Cancer Inst. 2023;115:570\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"3254_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-688","volume":"14","author":"JM Schildkraut","year":"2014","unstructured":"Schildkraut JM, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy M, Cote ML, et al. A multi-center population-based case-control study of ovarian cancer in African-American women: the African American Cancer Epidemiology Study (AACES). BMC Cancer. 2014;14:688.","journal-title":"BMC Cancer"},{"key":"3254_CR22","unstructured":"US Department of Health and Human Services. 2018 Physical Activity Guidelines Advisory Committee Scientific Report. (US Department of Health and Human Services, Washington D.C., U.S., 2018)."},{"key":"3254_CR23","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/01.mlr.0000163658.65008.ec","volume":"43","author":"S Chaudhry","year":"2005","unstructured":"Chaudhry S, Jin L, Meltzer D. Use of a self-report-generated Charlson Comorbidity Index for predicting mortality. Med Care. 2005;43:607\u201315.","journal-title":"Med Care"},{"key":"3254_CR24","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1002\/sim.3618","volume":"28","author":"IR White","year":"2009","unstructured":"White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med. 2009;28:1982\u201398.","journal-title":"Stat Med"},{"key":"3254_CR25","first-page":"131","volume":"4","author":"E Yoon","year":"2016","unstructured":"Yoon E, Babar A, Choudhary M, Kutner M, Pyrsopoulos N. Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update. J Clin Transl Hepatol. 2016;4:131\u201342.","journal-title":"J Clin Transl Hepatol"},{"key":"3254_CR26","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/FPC.0000000000000150","volume":"25","author":"LL Mazaleuskaya","year":"2015","unstructured":"Mazaleuskaya LL, Sangkuhl K, Thorn CF, FitzGerald GA, Altman RB, Klein TE. PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genom. 2015;25:416\u201326.","journal-title":"Pharmacogenet Genom"},{"key":"3254_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/096032718500400404","volume":"4","author":"DK Sommers","year":"1985","unstructured":"Sommers DK, van Staden DA, Moncrieff J, Schoeman HS. Paracetamol metabolism in African villagers. Hum Toxicol. 1985;4:385\u20139.","journal-title":"Hum Toxicol"},{"key":"3254_CR28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1124\/jpet.117.242107","volume":"362","author":"MH Court","year":"2017","unstructured":"Court MH, Zhu Z, Masse G, Duan SX, James LP, Harmatz JS, et al. Race, gender, and genetic polymorphism contribute to variability in acetaminophen pharmacokinetics, metabolism, and protein-adduct concentrations in healthy African-American and European-American volunteers. J Pharmacol Exp Ther. 2017;362:431\u201340.","journal-title":"J Pharmacol Exp Ther"},{"key":"3254_CR29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1365-2125.1986.tb02953.x","volume":"22","author":"JA Critchley","year":"1986","unstructured":"Critchley JA, Nimmo GR, Gregson CA, Woolhouse NM, Prescott LF. Inter-subject and ethnic differences in paracetamol metabolism. Br J Clin Pharmacol. 1986;22:649\u201357.","journal-title":"Br J Clin Pharmacol"},{"key":"3254_CR30","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/S1470-2045(19)30145-7","volume":"20","author":"SD Krens","year":"2019","unstructured":"Krens SD, Lassche G, Jansman FGA, Desar IME, Lankheet NAG, Burger DM, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol. 2019;20:e200\u20137.","journal-title":"Lancet Oncol"},{"key":"3254_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13330-2","volume":"24","author":"M Schmidt","year":"2024","unstructured":"Schmidt M, Vernooij R, van Nuland M, Smeijsters E, Devriese L, Mohammad NH, et al. Impaired liver function: effect on paclitaxel toxicity, dose modifications and overall survival. BMC Cancer. 2024;24:1553.","journal-title":"BMC Cancer"},{"key":"3254_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2021.105043","volume":"127","author":"R Weinstein","year":"2021","unstructured":"Weinstein R, Parikh-Das AM, Salonga R, Schuemie M, Ryan PB, Atillasoy E, et al. A systematic assessment of the epidemiologic literature regarding an association between acetaminophen exposure and cancer. Regul Toxicol Pharmacol. 2021;127:105043.","journal-title":"Regul Toxicol Pharmacol"},{"key":"3254_CR33","doi-asserted-by":"crossref","unstructured":"Fendrick AM, Pan DE, Johnson GE. OTC analgesics and drug interactions: clinical implications. Osteopath Med Prim Care. 2008;2:2.","DOI":"10.1186\/1750-4732-2-2"},{"key":"3254_CR34","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","volume":"147","author":"CW Tsao","year":"2023","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart Disease and Stroke Statistics-2023 Update: a report from the American Heart Association. Circulation. 2023;147:e93\u2013621.","journal-title":"Circulation"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03254-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03254-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03254-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:54:13Z","timestamp":1768917253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03254-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,31]]}},"alternative-id":["3254"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03254-4","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LCP reports research funding from Bristol Myers Squibb, Karyopharm and Janssen unrelated to this work. EVB served on a Pfizer Inc. Advisory Board to enhance minority participation in clinical trials unrelated to this work. No other conflicts of interest are reported by the other authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Institutional Review Board approval was obtained at the parent institution (Duke University, University of Virginia) and each individual study site, and informed consent was obtained for all participants. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}